154 Stock Overview
Designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InMode Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.03 |
| 52 Week High | US$24.76 |
| 52 Week Low | US$13.51 |
| Beta | 2.15 |
| 11 Month Change | 11.43% |
| 3 Month Change | 27.06% |
| 1 Year Change | -13.15% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 154 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 7.0% | 2.4% | 0.8% |
| 1Y | -13.2% | -5.0% | 9.1% |
Return vs Industry: 154 underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: 154 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 154 volatility | |
|---|---|
| 154 Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 154's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 154's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 581 | Moshe Mizrahy | www.inmodemd.com |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation.
InMode Ltd. Fundamentals Summary
| 154 fundamental statistics | |
|---|---|
| Market cap | €1.54b |
| Earnings (TTM) | €146.68m |
| Revenue (TTM) | €404.47m |
10.5x
P/E Ratio3.8x
P/S RatioIs 154 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 154 income statement (TTM) | |
|---|---|
| Revenue | US$423.75m |
| Cost of Revenue | US$77.80m |
| Gross Profit | US$345.95m |
| Other Expenses | US$192.28m |
| Earnings | US$153.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82 |
| Gross Margin | 81.64% |
| Net Profit Margin | 36.26% |
| Debt/Equity Ratio | 0% |
How did 154 perform over the long term?
See historical performance and comparison